Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $3.03 Average Target Price from Brokerages
Ovid Therapeutics Inc. (NASDAQ:OVID – Get Free Report) has received a consensus rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The […]
Ovid Therapeutics Inc. (NASDAQ:OVID – Get Free Report) has received a consensus rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The […]
